Gilead Financial Statements From 2010 to 2024

Stocks . USA . 
Stock . Gilead Sciences
GILD Stock  USD 92.92  0.35  0.38%   
Gilead Sciences financial statements provide useful quarterly and yearly information to potential Gilead Sciences investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Gilead Sciences financial statements helps investors assess Gilead Sciences' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Gilead Sciences' valuation are summarized below:
Gross Profit
21.6 B
Profit Margin
0.0045
Market Capitalization
115.4 B
Enterprise Value Revenue
4.7203
Revenue
28.3 B
There are over one hundred nineteen available fundamental trends for Gilead Sciences, which can be analyzed over time and compared to other ratios. Investors should ensure to confirm all of Gilead Sciences' regular performance against the performance from 2010 to 2024 to make sure the company is sustainable down the road. The current year's Market Cap is expected to grow to about 108.5 B. The current year's Enterprise Value is expected to grow to about 106.5 B

Gilead Sciences Total Revenue

28.47 Billion

Check Gilead Sciences financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Gilead Sciences' main balance sheet or income statement drivers, such as Interest Expense of 534.5 M, Total Revenue of 28.5 B or Gross Profit of 28.5 B, as well as many indicators such as Price To Sales Ratio of 3.54, Dividend Yield of 0.0268 or PTB Ratio of 7.87. Gilead financial statements analysis is a perfect complement when working with Gilead Sciences Valuation or Volatility modules.
  
Check out the analysis of Gilead Sciences Correlation against competitors.
For information on how to trade Gilead Stock refer to our How to Trade Gilead Stock guide.

Gilead Sciences Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets65.2 B62.1 B48.5 B
Slightly volatile
Short and Long Term Debt Total26.2 B25 B19.8 B
Slightly volatile
Other Current Liabilities8.1 B7.7 B6.3 B
Slightly volatile
Total Current Liabilities11.8 B11.3 B8.5 B
Slightly volatile
Total Stockholder Equity24 B22.8 B17 B
Slightly volatile
Property Plant And Equipment Net5.6 B5.3 B3.2 B
Slightly volatile
Accounts Payable518.2 M550 M864.5 M
Pretty Stable
Cash3.8 B6.1 B7.2 B
Very volatile
Non Current Assets Total48.3 B46 B28.2 B
Slightly volatile
Cash And Short Term Investments7.5 B7.3 B14.5 B
Very volatile
Common Stock Shares Outstanding1.5 B1.3 B1.3 B
Very volatile
Liabilities And Stockholders Equity65.2 B62.1 B48.5 B
Slightly volatile
Non Current Liabilities Total29.5 B28.1 B23 B
Slightly volatile
Other Current Assets1.3 B2.4 B1.8 B
Pretty Stable
Other Stockholder Equity6.8 B6.5 B3.6 B
Slightly volatile
Total Liabilities41.3 B39.4 B31.5 B
Slightly volatile
Total Current Assets10.8 B16.1 B19.9 B
Pretty Stable
Short Term Debt1.9 B1.8 B1.4 B
Slightly volatile
Net Receivables2.4 B4.7 B3.5 B
Slightly volatile
Property Plant And Equipment Gross8.2 B7.8 B3.8 B
Slightly volatile
Short Term Investments1.1 B1.2 B3.6 B
Pretty Stable
Inventory1.3 B1.8 B1.7 B
Slightly volatile
Other Liabilities8.8 B8.4 B6.4 B
Slightly volatile
Other Assets1.1 M1.1 M1.8 B
Pretty Stable
Long Term Debt12.2 B23.2 B17.9 B
Slightly volatile
Common Stock Total Equity892.4 K1.1 M1 M
Pretty Stable
Capital Stock901 K1.1 M1 M
Pretty Stable
Common Stock901 K1.1 M1 M
Pretty Stable
Property Plant Equipment6.6 B6.3 B3.3 B
Slightly volatile
Good Will10 B9.6 B4.3 B
Slightly volatile
Long Term Debt Total19.7 B26.4 B19.2 B
Slightly volatile
Capital Surpluse2.7 B5 B3.3 B
Very volatile
Long Term Investments1.1 B1.2 B3.8 B
Pretty Stable
Non Current Liabilities Other1.2 B1.3 B3.4 B
Slightly volatile
Deferred Long Term Asset Charges234.5 M462.3 M312.2 M
Slightly volatile
Intangible Assets16.7 B26.5 B16.2 B
Slightly volatile
Warrants1.7 M1.8 M6.3 M
Slightly volatile
Short and Long Term Debt3.5 B1.8 B3.3 B
Very volatile
Net Invested Capital39 B47.8 B50.6 B
Slightly volatile
Net Working Capital9.5 B4.8 B15.6 B
Slightly volatile

Gilead Sciences Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Interest Expense534.5 M944 M701.8 M
Slightly volatile
Total Revenue28.5 B27.1 B21.5 B
Slightly volatile
Gross Profit28.5 B27.1 B18.2 B
Slightly volatile
Other Operating Expenses20.5 B19.5 B12.1 B
Slightly volatile
Total Operating Expenses12.4 B11.8 B7.7 B
Slightly volatile
Research Development6 B5.7 B4.1 B
Slightly volatile
Selling General Administrative6.8 B6.5 B3.5 B
Slightly volatile
Net Income Applicable To Common Shares4.9 B5.3 B5.9 B
Very volatile
Net Income From Continuing Ops6.6 B5.8 B6.2 B
Very volatile
Selling And Marketing Expenses650.2 M826 M537.5 M
Slightly volatile
Interest Income194.1 M204.3 M506.6 M
Slightly volatile
Non Recurring4.4 B4.2 B1.8 B
Slightly volatile
Reconciled Depreciation1.9 B2.5 B1.5 B
Slightly volatile

Gilead Sciences Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Begin Period Cash Flow3.5 B5.4 B6.9 B
Pretty Stable
Depreciation2.8 B2.7 B1.3 B
Slightly volatile
Capital Expenditures614.2 M585 M551.2 M
Slightly volatile
End Period Cash Flow3.7 B6.1 B7.2 B
Very volatile
Stock Based Compensation423.9 M795 M468.5 M
Slightly volatile
Dividends Paid3.4 B3.8 B3.1 B
Pretty Stable
Issuance Of Capital Stock295.9 M382 M281.5 M
Very volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio3.543.728414.0019
Slightly volatile
Dividend Yield0.02680.03770.0261
Slightly volatile
PTB Ratio7.874.42786.5736
Slightly volatile
Days Sales Outstanding59.5962.7268854
Slightly volatile
Book Value Per Share19.1418.228412.8005
Slightly volatile
Stock Based Compensation To Revenue0.02710.02930.0218
Slightly volatile
Capex To Depreciation0.210.21720.5225
Slightly volatile
PB Ratio7.874.42786.5736
Slightly volatile
EV To Sales4.24.425513.9079
Slightly volatile
Inventory Turnover3.823.63632.6454
Slightly volatile
Days Of Inventory On Hand95.36100181
Slightly volatile
Sales General And Administrative To Revenue0.30.19410.2062
Pretty Stable
Research And Ddevelopement To Revenue0.240.25530.6058
Slightly volatile
Capex To Revenue0.02050.02160.0394
Slightly volatile
Cash Per Share3.085.82058.1005
Pretty Stable
Payout Ratio0.640.67242.9325
Pretty Stable
Income Quality1.361.42637.4515
Pretty Stable
Current Ratio1.351.4262.7524
Slightly volatile
Receivables Turnover3.95.81895.2754
Slightly volatile
Graham Number45.3943.227333.2407
Slightly volatile
Shareholders Equity Per Share19.2118.295712.8097
Slightly volatile
Debt To Equity1.151.09431.0884
Slightly volatile
Capex Per Share0.490.46880.4158
Slightly volatile
Revenue Per Share22.8121.727616.1898
Slightly volatile
Interest Debt Per Share21.8220.77815.9609
Slightly volatile
Debt To Assets0.420.40220.3874
Slightly volatile
Operating Cycle1551631 K
Slightly volatile
Price Book Value Ratio7.874.42786.5736
Slightly volatile
Dividend Payout Ratio0.640.67242.9325
Pretty Stable
Ebt Per Ebit0.690.90190.8933
Pretty Stable
Company Equity Multiplier1.582.72082.6064
Slightly volatile
Long Term Debt To Capitalization0.530.50390.4743
Slightly volatile
Total Debt To Capitalization0.550.52250.4988
Slightly volatile
Debt Equity Ratio1.151.09431.0884
Slightly volatile
Quick Ratio1.21.26762.5311
Slightly volatile
Net Income Per E B T0.940.82590.7417
Pretty Stable
Cash Ratio0.510.53951.3626
Slightly volatile
Cash Conversion Cycle126132135
Pretty Stable
Days Of Inventory Outstanding95.36100181
Slightly volatile
Days Of Sales Outstanding59.5962.7268854
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.120.92690.9576
Very volatile
Price To Book Ratio7.874.42786.5736
Slightly volatile
Fixed Asset Turnover5.025.09997.5727
Slightly volatile
Debt Ratio0.420.40220.3874
Slightly volatile
Price Sales Ratio3.543.728414.0019
Slightly volatile
Asset Turnover0.320.43650.4306
Pretty Stable
Gross Profit Margin1.070.76040.8692
Pretty Stable
Price Fair Value7.874.42786.5736
Slightly volatile

Gilead Sciences Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap108.5 B103.3 B98.1 B
Slightly volatile
Enterprise Value106.5 B101.5 B97.3 B
Slightly volatile

Gilead Fundamental Market Drivers

Forward Price Earnings12.2549
Cash And Short Term Investments7.3 B

Gilead Upcoming Events

6th of February 2024
Upcoming Quarterly Report
View
25th of April 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
6th of February 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Gilead Sciences Financial Statements

Gilead Sciences stakeholders use historical fundamental indicators, such as Gilead Sciences' revenue or net income, to determine how well the company is positioned to perform in the future. Although Gilead Sciences investors may analyze each financial statement separately, they are all interrelated. For example, changes in Gilead Sciences' assets and liabilities are reflected in the revenues and expenses on Gilead Sciences' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Gilead Sciences. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue-2.1 B-2 B
Total Revenue27.1 B28.5 B
Cost Of Revenue5.8 B6.1 B
Stock Based Compensation To Revenue 0.03  0.03 
Sales General And Administrative To Revenue 0.19  0.30 
Research And Ddevelopement To Revenue 0.26  0.24 
Capex To Revenue 0.02  0.02 
Revenue Per Share 21.73  22.81 
Ebit Per Revenue 0.28  0.29 

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
CCitigroup
GMGeneral Motors
FFord Motor
When determining whether Gilead Sciences is a strong investment it is important to analyze Gilead Sciences' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Gilead Sciences' future performance. For an informed investment choice regarding Gilead Stock, refer to the following important reports:
How To Invest In Gilead
Details
Is Gilead Stock a good investment?
Details
What is Gilead Sciences' Net Worth?
Details
Largest Biotechnology Companies
View
Largest Pharmaceuticals, Biotechnology & Life Sciences Companies
View
Check out the analysis of Gilead Sciences Correlation against competitors.
For information on how to trade Gilead Stock refer to our How to Trade Gilead Stock guide.
You can also try the ETF Categories module to list of ETF categories grouped based on various criteria, such as the investment strategy or type of investments.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Gilead Sciences. If investors know Gilead will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Gilead Sciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.42)
Dividend Share
3.06
Earnings Share
0.09
Revenue Per Share
22.703
Quarterly Revenue Growth
0.07
The market value of Gilead Sciences is measured differently than its book value, which is the value of Gilead that is recorded on the company's balance sheet. Investors also form their own opinion of Gilead Sciences' value that differs from its market value or its book value, called intrinsic value, which is Gilead Sciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Gilead Sciences' market value can be influenced by many factors that don't directly affect Gilead Sciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Altman
Z Score
Details
Piotroski
F Score
Details
Beneish
M Score
Details
Financial
Analysis
Details
Buy or Sell
Advice
Details
Earnings
Projections
Details
Please note, there is a significant difference between Gilead Sciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Gilead Sciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Gilead Sciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY